Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Hypoxia-activated Prodrug TH-4000

Known as: TH-4000 
A proprietary, hypoxia-activated prodrug with potential antineoplastic activity. Upon administration, the hypoxia-activated prodrug TH-4000 is… Expand
National Institutes of Health

Related topics

Related topics

2 relations
PR610Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
TH-4000, a hypoxia-activated EGFR/Her2 inhibitor to treat EGFR-TKI resistant T790M-negative NSCLC.
e13548 Background: TH-4000 is a clinical-stage hypoxia-activated prodrug that releases an irreversible tyrosine kinase inhibitor… Expand
Review
2015
Review
2015
Abstract 5358: The hypoxia-activated EGFR-TKI TH-4000 overcomes erlotinib-resistance in preclinical NSCLC models at plasma levels achieved in a Phase 1 clinical trial
Clinical data indicate that mutant EGFR NSCLC is often heterozygous (PLoS ONE 2013; 8: e54170; PLoS ONE 2009; 4: e7464) and the… Expand
2015
2015
The Hypoxia-Activated EGFR-TKI TH-4000: Preclinical Profile and Ongoing Clinical Studies in NSCLC, SCCHN, and SCCS
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE